- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Success with pemphigus vulgaris
Boston - A combination of Rituxan (rituximab, Genentech) and intravenous immune globulin (IVIG) can be effective in patients with severe refractory pemphigus vulgaris, a study in the New England Journal of Medicine reports.
Boston - A combination of Rituxan (rituximab, Genentech) and intravenous immune globulin (IVIG) can be effective in patients with severe refractory pemphigus vulgaris, a study in the New England Journal of Medicine reports.
Nine of 11 patients with severe disease had remissions lasting up to three years when treated with a combination of Rituxan and IVIG, according to http://MedPageToday.com/.
Two additional patients had complete resolution of lesions after additional infusions of Rituxan alone.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
